ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors

From the U.S., under to American Diabetes Association, diabetic ketoacidosis (DKA) is accountable for around 6.3 percent of all hospitalization and 0.4% of all mortality annually. Unregulated hyperglycemia (>250 mg/dL), significant anion gaps, metabolic acidosis, and an increased plasma ketone concentration are the manifestations of diabetic ketoacidosis. Despite this, DKA can occur in the vicinity of an average bloodstream sugar level (less than 200 mg/dL); this is described as euglycemic DKA (eu-DKA). The Sodium-glucose Cotransporter-2 (SGLT2) inhibitors are being used in the management of type 2 diabetes, given its favorable side effect of weight loss and improved cardiovascular mortality. Still, at the same, can cause in rare occasions eu-DKA. The hospitalization of a patient taking Empagliflozin at home presented to the emergency department complaining of shortness of breath, fever, chills, and productive cough for one week with eu-DKA and extreme acidemia in the setting of a confirmed COVID-19 infection that had remained persistent for eight days before presentations are described in this medical abstract. Eu-DKA is uncommon in the population, which increases the possibility of misdiagnosis in patients. In light of the COVID-19 epidemic, there is an immediate demand for increased public knowledge of the condition. Keywords: COVID-19, Diabetes, Glucose Metabolism, SARS-2, SGLT2 Inhibitor, Type 2 Diabetes Presentation: No date and time listed